[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Bushick et al., 1989 - Google Patents

Pursuit abnormal coagulation screening tests generates modest hidden preoperative costs

Bushick et al., 1989

Document ID
1359910513010400565
Author
Bushick J
Eisenberg J
Kinman J
Cebul R
Schwartz J
Publication year
Publication venue
Journal of General Internal Medicine

External Links

Snippet

To measure the follow-up costs of preoperative coagulation screening tests, the authors studied 829 consecutive patients undergoing inpatient orthopedic surgery. The results of the initial prothrombin and activated partial thromboplastin time tests were divided into three …
Continue reading at link.springer.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/36—Computer-assisted acquisition of medical data, e.g. computerised clinical trials or questionnaires
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Similar Documents

Publication Publication Date Title
Jayasinghe et al. Bleeding disorders in teenagers presenting with menorrhagia
Korte et al. Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism
Oberladstätter et al. A prospective observational study of the rapid detection of clinically‐relevant plasma direct oral anticoagulant levels following acute traumatic injury
Thomas et al. Hypercoagulability in venous and arterial thrombosis
Kamal et al. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults
Steiner et al. Bleeding time in uremia: a useful test to assess clinical bleeding
Kulkarni et al. Renal disease among males with haemophilia
Woodward et al. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women: the Scottish Heart Health Study
Podda et al. Usefulness of PFA‐100® testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time
Hayward How I investigate for bleeding disorders
Trossaert et al. Diagnosis and management challenges in patients with mild haemophilia A and discrepant FVIII measurements
Shah et al. Characterization of the hypercoagulable state in patients with sickle cell disease
Wool Benefits and pitfalls of point-of-care coagulation testing for anticoagulation management: an ACLPS critical review
Erban et al. Routine use of the prothrombin and partial thromboplastin times
Zakai et al. Activated partial thromboplastin time and risk of future venous thromboembolism
Onishi et al. A pathological clarification of sepsis-associated disseminated intravascular coagulation based on comprehensive coagulation and fibrinolysis function
Bushick et al. Pursuit abnormal coagulation screening tests generates modest hidden preoperative costs
Favaloro et al. Laboratory testing for activated protein C resistance: rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC Stop to neutralise interference
Tagariello et al. Clinical relevance of isolated prolongation of the activated partial thromboplastin time in a cohort of adults undergoing surgical procedures
Eisenberg et al. Clinical usefulness of measuring prothrombin time as a routine admission test.
Regling et al. Utility of thromboelastography for the diagnosis of von Willebrand disease
Jenrette et al. Evaluation of direct oral anticoagulant use on thromboelastography in an emergency department population
Shaw et al. Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure
Soman et al. Greek stroke score, Siriraj score and Allen score in clinical diagnosis of intracerebral hemorrhage and infarct: validation and comparison study
Horlocker et al. Effect of age, gender, and platelet count on Sonoclot coagulation analysis in patients undergoing orthopedic operations